Victor Sarli Issa
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Research Interests
Victor Sarli Issa has a total of 55 co-authors. Here are the top co-authors by number of shared publications:
Edimar Alcides Bocchi
Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
6 shared publications- Guilherme Veiga Guimarães
Instituto do Coração, Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, SP, Brazil
4 shared publications Silvia Moreira Ayub-Ferreira
Heart Institute (InCor) do Hospital das Clínicas da Faculdade de Medicina da Universidade de São Paulo, São Paulo, Brazil
4 shared publications- Silvia Moreira Ayub-Ferreira
Universidade de São Paulo
4 shared publications Edimar A. Bocchi
3 shared publicationsPaulo R. Chizzola
3 shared publications
Latest Publications
- 29 June 2022
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 2 (2) , 152-156
Cognitive Frailty and Depressive Symptoms in Heart Transplant Candidates: Rational and Study Design
Background: Patients with advanced heart disease have impaired cognitive abilities and higher probability of depressive symptoms. These factors contribute to negative outcomes of treatment, such as the development of comorbidities, higher hospitalization and mortality rates, poor treatment compliance and self-care, and decrease in quality of life and functionality. Objective: To describe the prevalence and to evaluate the impact of cognitive frailty in patients in the waiting list of heart transplantation, with death while waiting transplantation and priority transplantation as [...] Abstract Background: Patients with advanced heart disease have impaired cognitive abilities and higher probability of depressive symptoms. These factors contribute to negative outcomes of treatment, such as the development of comorbidities, higher hospitalization and mortality rates, poor treatment compliance and self-care, and decrease in quality of life and functionality. Objective: To describe the prevalence and to evaluate the impact of cognitive frailty in patients in the waiting list of heart transplantation, with death while waiting transplantation and priority transplantation as
- 29 June 2022
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 2 (2) , 152-156
Cognitive Frailty and Depressive Symptoms in Heart Transplant Candidates: Rational and Study Design
Background: Patients with advanced heart disease have impaired cognitive abilities and higher probability of depressive symptoms. These factors contribute to negative outcomes of treatment, such as the development of comorbidities, higher hospitalization and mortality rates, poor treatment compliance and self-care, and decrease in quality of life and functionality. Objective: To describe the prevalence and to evaluate the impact of cognitive frailty in patients in the waiting list of heart transplantation, with death while waiting transplantation and priority transplantation as [...] Abstract Background: Patients with advanced heart disease have impaired cognitive abilities and higher probability of depressive symptoms. These factors contribute to negative outcomes of treatment, such as the development of comorbidities, higher hospitalization and mortality rates, poor treatment compliance and self-care, and decrease in quality of life and functionality. Objective: To describe the prevalence and to evaluate the impact of cognitive frailty in patients in the waiting list of heart transplantation, with death while waiting transplantation and priority transplantation as
- 29 June 2022
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 2 (2) , 195-197
Is There Room for New Drugs in the Treatment of Advanced Heart Failure: SGLT2i?
Over the last years, we have witnessed the inclusion of the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for the treatment of patients with heart failure. Drugs in this group share the fact that they are able to inhibit glucose transport in the proximal tubule and thus promote glycosuria and blood glucose reduction in patients with diabetes. Other effects of these medications include increasing diuresis and natriuresis, lowering blood pressure, stimulating erythropoiesis, improving cardiac energy metabolism, reducing inflammation, inhibiting the [...] Over the last years, we have witnessed the inclusion of the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for the treatment of patients with heart failure. Drugs in this group share the fact that they are able to inhibit glucose transport in the proximal tubule and thus promote glycosuria and blood glucose reduction in patients with diabetes. Other effects of these medications include increasing diuresis and natriuresis, lowering blood pressure, stimulating erythropoiesis, improving cardiac energy metabolism, reducing inflammation, inhibiting the
- 29 June 2022
- Published by Sociedade Brasileira de Cardiologia in ABC Heart Failure & Cardiomyopathy
- Vol. 2 (2) , 195-197
Is There Room for New Drugs in the Treatment of Advanced Heart Failure: SGLT2i?
Over the last years, we have witnessed the inclusion of the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for the treatment of patients with heart failure. Drugs in this group share the fact that they are able to inhibit glucose transport in the proximal tubule and thus promote glycosuria and blood glucose reduction in patients with diabetes. Other effects of these medications include increasing diuresis and natriuresis, lowering blood pressure, stimulating erythropoiesis, improving cardiac energy metabolism, reducing inflammation, inhibiting the [...] Over the last years, we have witnessed the inclusion of the use of sodium-glucose cotransporter 2 inhibitors (SGLT2i) for the treatment of patients with heart failure. Drugs in this group share the fact that they are able to inhibit glucose transport in the proximal tubule and thus promote glycosuria and blood glucose reduction in patients with diabetes. Other effects of these medications include increasing diuresis and natriuresis, lowering blood pressure, stimulating erythropoiesis, improving cardiac energy metabolism, reducing inflammation, inhibiting the
- Open Access
- 1 January 2019
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 112 (6) , 793-802
Young Male with Intense Dyspnea, Pulmonary Infiltrate, Normal Cardiac Area and Obliteration of the Apical Portion of the Left Ventricle
- 1 January 2019
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 112 (6) , 793-802
Open AccessYoung Male with Intense Dyspnea, Pulmonary Infiltrate, Normal Cardiac Area and Obliteration of the Apical Portion of the Left Ventricle
- Open Access
- 6 December 2018
- Published by BMJ in Open Heart
- Vol. 5 (2) , e000923
Prognosis and risk stratification in patients with decompensated heart failure receiving inotropic therapy
Objectives The prognostic significance of transient use of inotropes has been sufficiently studied in recent heart failure (HF) populations. We hypothesised that risk stratification in these patients could contribute to patient selection for advanced therapies. Methods We analysed a prospective cohort of adult patients admitted with decompensated HF and ejection fraction (left ventricular ejection fraction (LVEF)) less than 50%. We explored the outcomes of patients requiring inotropic therapy during hospital admission and after discharge. Results The study included 737 patients, (64.0% male), with a median age of 58 years (IQR 48–66 years). Main aetiologies were dilated cardiomyopathy in 273 (37.0%) patients, ischaemic heart disease in 195 (26.5%) patients and Chagas disease in 163 (22.1%) patients. Median LVEF was 26 % (IQR 22%–35%). Inotropes were used in 518 (70.3%) patients. In 431 (83.2%) patients, a single inotrope was administered. Inotropic therapy was associated with higher risk of in-hospital death/urgent heart transplant (OR=10.628, 95% CI 5.055 to 22.344, pConclusions Inotropic drugs are still widely used in patients with advanced decompensated HF and are associated with a worse in-hospital prognosis. In contrast with previous results, intermittent use of inotropes during hospitalisation did not determine a worse prognosis at 180-day follow-up. These data may add to prognostic evaluation in patients with advanced HF in centres where mechanical circulatory support is not broadly available.
- 6 December 2018
- Published by BMJ in Open Heart
- Vol. 5 (2) , e000923
Open AccessPrognosis and risk stratification in patients with decompensated heart failure receiving inotropic therapy
Objectives The prognostic significance of transient use of inotropes has been sufficiently studied in recent heart failure (HF) populations. We hypothesised that risk stratification in these patients could contribute to patient selection for advanced therapies. Methods We analysed a prospective cohort of adult patients admitted with decompensated HF and ejection fraction (left ventricular ejection fraction (LVEF)) less than 50%. We explored the outcomes of patients requiring inotropic therapy during hospital admission and after discharge. Results The study included 737 patients, (64.0% male), with a median age of 58 years (IQR 48–66 years). Main aetiologies were dilated cardiomyopathy in 273 (37.0%) patients, ischaemic heart disease in 195 (26.5%) patients and Chagas disease in 163 (22.1%) patients. Median LVEF was 26 % (IQR 22%–35%). Inotropes were used in 518 (70.3%) patients. In 431 (83.2%) patients, a single inotrope was administered. Inotropic therapy was associated with higher risk of in-hospital death/urgent heart transplant (OR=10.628, 95% CI 5.055 to 22.344, pConclusions Inotropic drugs are still widely used in patients with advanced decompensated HF and are associated with a worse in-hospital prognosis. In contrast with previous results, intermittent use of inotropes during hospitalisation did not determine a worse prognosis at 180-day follow-up. These data may add to prognostic evaluation in patients with advanced HF in centres where mechanical circulatory support is not broadly available.
- 13 April 2018
- Published by Elsevier in Cardiovascular Pathology
- Vol. 35, 23-28
Thromboembolic Findings in Patients with Heart Failure at Autopsy
- 13 April 2018
- Published by Elsevier in Cardiovascular Pathology
- Vol. 35, 23-28
Thromboembolic Findings in Patients with Heart Failure at Autopsy
- Open Access
- 12 February 2018
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 12 (2) , e0006207
Clinical findings and prognosis of patients hospitalized for acute decompensated heart failure: Analysis of the influence of Chagas etiology and ventricular function
Explore the association between clinical findings and prognosis in patients with acute decompensated heart failure (ADHF) and analyze the influence of etiology on clinical presentation and prognosis. Prospective cohort of 500 patients admitted with ADHF from Aug/2013-Feb/2016; patients were predominantly male (61.8%), median age was 58 (IQ25-75% 47–66 years); etiology was dilated cardiomyopathy in 141 (28.2%), ischemic heart disease in 137 (27.4%), and Chagas heart disease in 113 (22.6%). Patients who died (154 [30.8%]) or underwent heart transplantation (53[10.6%]) were younger (56 years [IQ25-75% 45–64 vs 60 years, IQ25-75% 49–67], P = 0.032), more frequently admitted for cardiogenic shock (20.3% vs 6.8%, P25-75% 4–32.8 vs 7.5 days, IQ25-75% 2–31], P = 0.004), had signs of congestion (90.8% vs 76.5%, PP25-75% 80–100 vs 100, IQ25-75% 90–120], PPP = 0.004, OR 1.923 [95%CI 1.232–3.001]) were significant. Chagas patients were more frequently admitted for cardiogenic shock (15%) and syncope/arrhythmia (20.4%). Pulmonary congestion was rare among Chagas patients and blood pressure was lower. The rate of in-hospital death or heart transplant was higher among patients with Chagas (50.5%). A physical exam may identify patients at higher risk in a contemporaneous population. Our findings support specific therapies targeted at Chagas patients in the setting of ADHF. It is recognized that the clinical evaluation of patients remains the basis for the characterization of diseases, data interpretation, and patient care. However, incorporation of technological methods into clinical practice has challenged the way cardiologists’ value of history and clinical examination. The present study sought to analyze the importance of clinical findings in a contemporaneous cohort of patients admitted with decompensated heart failure. Our results indicate that the physical exam may identify patients at higher risk in a contemporaneous patient population, and that clinical presentation varies according to etiology—especially Chagas disease—and ventricular function. Our findings support the need of development of specific therapeutic approaches targeted at Chagas patients in the setting of acute decompensated heart failure, as they represent a more vulnerable population.
- 12 February 2018
- Published by Public Library of Science (PLoS) in PLOS Neglected Tropical Diseases
- Vol. 12 (2) , e0006207
Open AccessClinical findings and prognosis of patients hospitalized for acute decompensated heart failure: Analysis of the influence of Chagas etiology and ventricular function
Explore the association between clinical findings and prognosis in patients with acute decompensated heart failure (ADHF) and analyze the influence of etiology on clinical presentation and prognosis. Prospective cohort of 500 patients admitted with ADHF from Aug/2013-Feb/2016; patients were predominantly male (61.8%), median age was 58 (IQ25-75% 47–66 years); etiology was dilated cardiomyopathy in 141 (28.2%), ischemic heart disease in 137 (27.4%), and Chagas heart disease in 113 (22.6%). Patients who died (154 [30.8%]) or underwent heart transplantation (53[10.6%]) were younger (56 years [IQ25-75% 45–64 vs 60 years, IQ25-75% 49–67], P = 0.032), more frequently admitted for cardiogenic shock (20.3% vs 6.8%, P25-75% 4–32.8 vs 7.5 days, IQ25-75% 2–31], P = 0.004), had signs of congestion (90.8% vs 76.5%, PP25-75% 80–100 vs 100, IQ25-75% 90–120], PPP = 0.004, OR 1.923 [95%CI 1.232–3.001]) were significant. Chagas patients were more frequently admitted for cardiogenic shock (15%) and syncope/arrhythmia (20.4%). Pulmonary congestion was rare among Chagas patients and blood pressure was lower. The rate of in-hospital death or heart transplant was higher among patients with Chagas (50.5%). A physical exam may identify patients at higher risk in a contemporaneous population. Our findings support specific therapies targeted at Chagas patients in the setting of ADHF. It is recognized that the clinical evaluation of patients remains the basis for the characterization of diseases, data interpretation, and patient care. However, incorporation of technological methods into clinical practice has challenged the way cardiologists’ value of history and clinical examination. The present study sought to analyze the importance of clinical findings in a contemporaneous cohort of patients admitted with decompensated heart failure. Our results indicate that the physical exam may identify patients at higher risk in a contemporaneous patient population, and that clinical presentation varies according to etiology—especially Chagas disease—and ventricular function. Our findings support the need of development of specific therapeutic approaches targeted at Chagas patients in the setting of acute decompensated heart failure, as they represent a more vulnerable population.
- Open Access
- 1 January 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (4) , e5978
Diagnostic discrepancies in clinical practice
Autopsies are the gold standard for diagnostic accuracy; however, no recent study has analyzed autopsies in heart failure (HF). We reviewed 1241 autopsies (January 2000–May 2005) and selected 232 patients with HF. Clinical and autopsy diagnoses were analyzed and discrepancies categorized according to their importance regarding therapy and prognosis. Mean age was 63.3 ± 15.9 years; 154 (66.4%) patients were male. The causes of death at autopsy were end-stage HF (40.9%), acute myocardial infarction (17.2%), infection (15.9), and pulmonary embolism 36 (15.5). Diagnostic discrepancies occurred in 191 (82.3%) cases; in 56 (24.1%), discrepancies were related to major diagnoses with potential influence on survival or treatment; pulmonary embolism was the cause of death for 24 (42.9%) of these patients. In 35 (15.1%), discrepancies were related to a major diagnosis with equivocal influence on survival or treatment; in 100 (43.1%), discrepancies did not influence survival or treatment. In multivariate analysis, age (OR: 1.03, 95% CI: 1.008–1.052, P = 0.007) and presence of diabetes mellitus (OR: 0.359, 95% CI: 0.168–0.767, P = 0.008) influenced the occurrence discrepancies. Diagnostic discrepancies with a potential impact on prognosis are frequent in HF. These findings warrant reconsideration in diagnostic and therapeutic practices with HF patients.
- 1 January 2017
- Published by Wolters Kluwer Health in Medicine
- Vol. 96 (4) , e5978
Open AccessDiagnostic discrepancies in clinical practice
Autopsies are the gold standard for diagnostic accuracy; however, no recent study has analyzed autopsies in heart failure (HF). We reviewed 1241 autopsies (January 2000–May 2005) and selected 232 patients with HF. Clinical and autopsy diagnoses were analyzed and discrepancies categorized according to their importance regarding therapy and prognosis. Mean age was 63.3 ± 15.9 years; 154 (66.4%) patients were male. The causes of death at autopsy were end-stage HF (40.9%), acute myocardial infarction (17.2%), infection (15.9), and pulmonary embolism 36 (15.5). Diagnostic discrepancies occurred in 191 (82.3%) cases; in 56 (24.1%), discrepancies were related to major diagnoses with potential influence on survival or treatment; pulmonary embolism was the cause of death for 24 (42.9%) of these patients. In 35 (15.1%), discrepancies were related to a major diagnosis with equivocal influence on survival or treatment; in 100 (43.1%), discrepancies did not influence survival or treatment. In multivariate analysis, age (OR: 1.03, 95% CI: 1.008–1.052, P = 0.007) and presence of diabetes mellitus (OR: 0.359, 95% CI: 0.168–0.767, P = 0.008) influenced the occurrence discrepancies. Diagnostic discrepancies with a potential impact on prognosis are frequent in HF. These findings warrant reconsideration in diagnostic and therapeutic practices with HF patients.
- Open Access
- 1 January 2015
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 105 (3) , 265-75
Reverse Auction: A Potential Strategy for Reduction of Pharmacological Therapy Cost
Polypharmacy is a significant economic burden. We tested whether using reverse auction (RA) as compared with commercial pharmacy (CP) to purchase medicine results in lower pharmaceutical costs for heart failure (HF) and heart transplantation (HT) outpatients. We compared the costs via RA versus CP in 808 HF and 147 HT patients followed from 2009 through 2011, and evaluated the influence of clinical and demographic variables on cost. The monthly cost per patient for HF drugs acquired via RA was $10.15 (IQ 3.51-40.22) versus $161.76 (IQ 86.05‑340.15) via CP; for HT, those costs were $393.08 (IQ 124.74-774.76) and $1,207.70 (IQ 604.48-2,499.97), respectively. RA may reduce the cost of prescription drugs for HF and HT, potentially making HF treatment more accessible. Clinical characteristics can influence the cost and benefits of RA. RA may be a new health policy strategy to reduce costs of prescribed medications for HF and HT patients, reducing the economic burden of treatment.
- 1 January 2015
- Published by Sociedade Brasileira de Cardiologia in Arquivos Brasileiros de Cardiologia
- Vol. 105 (3) , 265-75
Open AccessReverse Auction: A Potential Strategy for Reduction of Pharmacological Therapy Cost
Polypharmacy is a significant economic burden. We tested whether using reverse auction (RA) as compared with commercial pharmacy (CP) to purchase medicine results in lower pharmaceutical costs for heart failure (HF) and heart transplantation (HT) outpatients. We compared the costs via RA versus CP in 808 HF and 147 HT patients followed from 2009 through 2011, and evaluated the influence of clinical and demographic variables on cost. The monthly cost per patient for HF drugs acquired via RA was $10.15 (IQ 3.51-40.22) versus $161.76 (IQ 86.05‑340.15) via CP; for HT, those costs were $393.08 (IQ 124.74-774.76) and $1,207.70 (IQ 604.48-2,499.97), respectively. RA may reduce the cost of prescription drugs for HF and HT, potentially making HF treatment more accessible. Clinical characteristics can influence the cost and benefits of RA. RA may be a new health policy strategy to reduce costs of prescribed medications for HF and HT patients, reducing the economic burden of treatment.
- 1 July 2013
- Published by Elsevier in International Journal of Cardiology
- Vol. 167 (1) , 34-40
Hypertonic saline solution for prevention of renal dysfunction in patients with decompensated heart failure
- 1 July 2013
- Published by Elsevier in International Journal of Cardiology
- Vol. 167 (1) , 34-40
Hypertonic saline solution for prevention of renal dysfunction in patients with decompensated heart failure
- Open Access
Current strategies for preventing renal dysfunction in patients with heart failure: a heart failure stage approach
Renal dysfunction is common during episodes of acute decompensated heart failure, and historical data indicate that the mean creatinine level at admission has risen in recent decades. Different mechanisms underlying this change over time have been proposed, such as demographic changes, hemodynamic and neurohumoral derangements and medical interventions. In this setting, various strategies have been proposed for the prevention of renal dysfunction with heterogeneous results. In the present article, we review and discuss the main aspects of renal dysfunction prevention according to the different stages of heart failure.
Open AccessCurrent strategies for preventing renal dysfunction in patients with heart failure: a heart failure stage approach
Renal dysfunction is common during episodes of acute decompensated heart failure, and historical data indicate that the mean creatinine level at admission has risen in recent decades. Different mechanisms underlying this change over time have been proposed, such as demographic changes, hemodynamic and neurohumoral derangements and medical interventions. In this setting, various strategies have been proposed for the prevention of renal dysfunction with heterogeneous results. In the present article, we review and discuss the main aspects of renal dysfunction prevention according to the different stages of heart failure.